Conference abstractPublished 17 Nov 2015
Antifungal effect of silver nanoparticles versus miconazole oral gel/suspension in experimentallyinduced oral candidiasis in rats
1Thamar University, Yemen 2Suez Canal University, Egypt
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Aim: The present study assessed the antifungal activity of silver nanoparticles against experimentally-induced oral candidiasis compared to miconazole oral gel/suspension. Main methods: Oral candidiasis was induced in male rats using Candida albicans (ATCC 90028). One hundred and ninety two rats were assigned into six groups; 32 rats each. Group 1: rats without oral candidiasis (immunosuppressed/not infected); Group 2: rats with oral candidiasis (immunosuppressed/infected); Group 3: rats with oral candidiasis treated topically with 2% miconazole oral gel; Group 4: rats with oral candidiasis and treated topically with 2% miconazole aqueous suspension; Group 5: rats with oral candidiasis and treated topically with silver nanoparticle solution (50 Ã?¼g/ml); Group 6: rats with oral candidiasis and treated topically with silver nanoparticle solution (100 Ã?¼g/ml). All treatments were applied topically every day for 2 weeks. In vitro determination of Minimal Inhibitory Concentration (MIC) was performed using macro broth dilution method. Baseline assessment was conducted on day 0 (just before drug treatment). Macroscopic evaluation of the lesions, microbial counting and histopathological changes were evaluated on day 0, 7, day 14 and the follow up assessment was performed at day 28. Key findings: In vivo experiment indicated that silver nanoparticles provided a quicker and effective onset of antifungal activity with greater efficacy on day 7 only regarding all measured parameters compared to miconazole. However, the effect was generally equivalent to that provided by miconazole after day 14 and day 28. Significance: Silver nanoparticles may be considered as a promising candidate for treatment of oral C. albicans infections if clinical safety data are available.
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalClinical Pharmacology & Biopharmaceutics
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Sawsan A Zaitone”
- BylineArticles whose byline prints “Abdulrazzaq A Almaweri”
- BylineArticles whose byline prints “Marwa M Azab”
- BylineArticles whose byline prints “Abdel-Nasser M Al-Refai”
- BylineArticles whose byline prints “Salah M Abdalla”
- BylineArticles whose byline prints “Magda M Hassan”
- BylineArticles whose byline prints “Pierre A Hanna”